Lung Transplant Patients with RSV: Inhaled RNA Prevents BO?
www.pulmccm.org
In a very small trial (n=24), inhaled RNA (ALN-RSV01) appeared to improve outcomes in lung transplant patients with RSV respiratory infections, by interfering with viral replication. Symptoms were reduced, and at 90 days, incidence of bronchiolitis obliterans syndrome was 6% vs 50% in the control group.
Lung Transplant Patients with RSV: Inhaled RNA Prevents BO?
Lung Transplant Patients with RSV: Inhaled…
Lung Transplant Patients with RSV: Inhaled RNA Prevents BO?
In a very small trial (n=24), inhaled RNA (ALN-RSV01) appeared to improve outcomes in lung transplant patients with RSV respiratory infections, by interfering with viral replication. Symptoms were reduced, and at 90 days, incidence of bronchiolitis obliterans syndrome was 6% vs 50% in the control group.